- Home
- NTIP vs CRIS Comparison
NTIP vs CRIS Comparison
Compare NTIP & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- CRIS
- Stock Information
- Founded
- NTIP 1990
- CRIS 2000
- Country
- NTIP United States
- CRIS United States
- Employees
- NTIP N/A
- CRIS N/A
- Industry
- NTIP Multi-Sector Companies
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTIP Miscellaneous
- CRIS Health Care
- Exchange
- NTIP Nasdaq
- CRIS Nasdaq
- Market Cap
- NTIP 32.0M
- CRIS 18.6M
- IPO Year
- NTIP 1998
- CRIS 2000
- Fundamental
- Price
- NTIP $1.53
- CRIS $1.42
- Analyst Decision
- NTIP
- CRIS Strong Buy
- Analyst Count
- NTIP 0
- CRIS 2
- Target Price
- NTIP N/A
- CRIS $16.50
- AVG Volume (30 Days)
- NTIP 9.6K
- CRIS 71.2K
- Earning Date
- NTIP 10-24-2025
- CRIS 11-06-2025
- Dividend Yield
- NTIP 6.54%
- CRIS N/A
- EPS Growth
- NTIP N/A
- CRIS N/A
- EPS
- NTIP N/A
- CRIS N/A
- Revenue
- NTIP $150,000.00
- CRIS $11,405,000.00
- Revenue This Year
- NTIP N/A
- CRIS $2.72
- Revenue Next Year
- NTIP N/A
- CRIS $8.27
- P/E Ratio
- NTIP N/A
- CRIS N/A
- Revenue Growth
- NTIP N/A
- CRIS 12.24
- 52 Week Low
- NTIP $1.16
- CRIS $1.02
- 52 Week High
- NTIP $1.90
- CRIS $5.00
- Technical
- Relative Strength Index (RSI)
- NTIP 52.50
- CRIS 34.38
- Support Level
- NTIP $1.48
- CRIS $1.46
- Resistance Level
- NTIP $1.58
- CRIS $1.59
- Average True Range (ATR)
- NTIP 0.05
- CRIS 0.08
- MACD
- NTIP -0.00
- CRIS -0.01
- Stochastic Oscillator
- NTIP 58.30
- CRIS 0.00
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.